HIMS

Hims & Hers Health, Inc. (HIMS) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing access to licensed healthcare professionals, telehealth consultations, and pharmacy fulfillment for conditions including sexual health, dermatology, mental health, and weight loss. The company operates as a single reporting unit.

Key Financial Metrics

Note: Q2 2024 marked the company's first profitable quarter since inception. Cash and cash equivalents were $129.3 million, with short-term investments of $98.0 million as of June 30, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 52% year-over-year (Q2) and 49% year-over-year (YTD). Online revenue grew 53% to $306.8 million, driven by subscriber growth and higher Average Order Value (AOV).
• Profitability: The company transitioned from a net loss of $7.2 million in Q2 2023 to net income of $13.3 million in Q2 2024. Operating income was $11.0 million compared to an operating loss of $9.2 million in the prior year.
• Subscriber Metrics: Subscribers grew 43% to approximately 1.9 million. Monthly Online Revenue per Average Subscriber increased to $57 (up 8% YoY), and AOV increased to $121 (up 27% YoY).
• Expense Management: Marketing expenses increased 35% to $144.9 million, primarily due to increased customer acquisition costs. However, marketing as a percentage of revenue decreased from 51% to 46%.
• Share Repurchases: The company fully utilized its previous $50 million share repurchase program, retiring 3.6 million shares YTD for $48.0 million.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue investing in fulfillment capabilities, marketing, and product offerings. They believe current cash resources are sufficient to support operations for the next 12 months.
• New Repurchase Program: In July 2024, the Board authorized a new $100 million share repurchase program expiring August 31, 2027.
• Acquisition: In July 2024, the company executed an agreement to acquire a 503B compounding outsourcing facility for approximately $31 million to expand compounding capabilities.
• Risks:
  • Regulatory: Significant risks related to FDA regulations on compounded GLP-1s (weight loss drugs), telehealth laws, and pharmacy compliance.
  • Supply Chain: Potential shortages of branded GLP-1s and reliance on third-party manufacturers.
  • Competition: Intense competition from traditional healthcare providers, retailers, and other telehealth platforms.
  • Marketing: Dependence on digital advertising platforms and potential changes in privacy laws affecting customer acquisition.

Investor Verification Checklist

• Sustainability of Profitability: Verify if Q2 profitability is a trend or an anomaly given the heavy investment in marketing and operations.
• GLP-1 Supply & Regulation: Assess the stability of the supply chain for compounded semaglutide and the regulatory environment surrounding 503B facilities.
• Customer Acquisition Costs (CAC): Monitor the efficiency of marketing spend as the company scales; CAC increased significantly in absolute terms.
• Subscriber Retention: Evaluate long-term retention rates, particularly for weight loss subscriptions which may be sensitive to drug shortages or pricing changes.
• Capital Allocation: Review the execution of the new $100 million buyback program and the integration of the new compounding facility.